WO2008038002A2 - T cell therapies - Google Patents
T cell therapies Download PDFInfo
- Publication number
- WO2008038002A2 WO2008038002A2 PCT/GB2007/003676 GB2007003676W WO2008038002A2 WO 2008038002 A2 WO2008038002 A2 WO 2008038002A2 GB 2007003676 W GB2007003676 W GB 2007003676W WO 2008038002 A2 WO2008038002 A2 WO 2008038002A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- tcr
- transfected
- cell
- tcrs
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 177
- 238000002659 cell therapy Methods 0.000 title description 4
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 98
- 210000004027 cell Anatomy 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000003993 interaction Effects 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000009258 tissue cross reactivity Effects 0.000 claims 25
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract description 92
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 25
- 230000004913 activation Effects 0.000 abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 37
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 33
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 33
- 239000000427 antigen Substances 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 28
- 102000039446 nucleic acids Human genes 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 108020004705 Codon Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- 238000001994 activation Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108020004566 Transfer RNA Proteins 0.000 description 5
- 238000007413 biotinylation Methods 0.000 description 5
- 230000006287 biotinylation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000021633 leukocyte mediated immunity Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000012606 POROS 50 HQ resin Substances 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- -1 succinimidyl ester Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- This invention relates to a method of treating cancer or infection by administering T cells transfected with T cell receptors (TCRs) which in their soluble form have a half life for their interaction with their cognate peptide- MHC complex chosen to enhance the avidity of the T cells for target cells presenting that peptide MHC complex while maintaining the activation specificity of the T cells by that peptide-MHC complex.
- TCRs T cell receptors
- Immunotherapy involves enhancing the immune response of a patient to cancerous or infected cells. Active immunotherapy is carried out by stimulation of the endogenous immune system of tumour bearing patients. Passive, or adoptive, immunotherapy involves the transfer of immune competent cells into the patient. (Paul (2002) Curr Gene Therapy 2: 91-100) There are three broad approaches to adoptive immunotherapy which have been applied in the clinic for the treatment of metastatic diseases; lymphokine-activated killer (LAK) cells, auto-lymphocyte therapy (ALT) and tumour-infiltrating lymphocytes (TIL). (Paul (2002) Curr Gene Therapy 2: 91- 100).
- LAK lymphokine-activated killer
- ALT auto-lymphocyte therapy
- TIL tumour-infiltrating lymphocytes
- T cell adoptive therapy is the use of gene therapy techniques to introduce TCRs specific for known cancer-specific MHC-peptide complexes into the T cells of cancer patients.
- WO 01/55366 discloses retrovirus-based methods for transfecting, preferably, T cells with heterologous TCRs. This document states that these transfected cells could be used for either the cell surface display of TCR variants as a means of identifying high affinity TCRs or for immunotherapy. Methods for the molecular cloning of cDNA of a human p53-specific, HLA restricted murine TCR and the transfer of this cDNA to human T cells are described in published US patent application no. 20020064521.
- this document states that the expression of this murine TCR results in the recognition of endogenously processed human p53 expressed in tumour cells pulsed with the p53-derived peptide 149-157 presented by HLA A * 0201 and claims the use of the murine TCR in anticancer adoptive immunotherapy.
- the concentration of peptide pulsing required achieving half maximal T cell stimulation of the transfected T cells was approximately 250 times that required by T cells expressing solely the murine TCR.
- the difference in level of peptide sensitivity is what might be expected of a transfectant line that contained multiple different TCR heterodimers as a result of independent association of all four expressed hu and mu TCR chains.”
- a further study describes the administration of an expanded population of Melan-A specific cytotoxic T cells to eight patients with refractory malignant melanoma. These T cells were administered by i.v. infusion at fortnightly intervals, accompanied by s.c. administration of IL-2. The T cell infusions were well tolerated with clinical responses noted as one partial, one mixed with shrinkage of one metastatic deposit and one no change (12 months) among the eight patients.
- T-cells transfected with TCRs having high affinities for their cognate p-MHCs would produce the desired improvement in immune response.
- Phage display provides one means by which libraries of TCR variants can be generated. Methods suitable for the phage display and subsequent screening of libraries of TCR variants each containing a non-native disulfide interchain bond are detailed in (Li et a/., (2005) Nature Biotech 23 (3): 349-354) and WO 2004/04404.
- This invention is based on the results of experiments which seek to establish the characteristic of the T cell activation process determinative of increased pMHC-specific T cell mediated immune response.
- the data has shown that pMHC-specific T-cell mediated immune responses can be enhanced if the T- cells are transfected with TCRs which, in soluble form, have a half life for their interaction with their cognate peptide-MHC ligands in a particular range. This has enabled us to place numerical limits on the effective range of those half lives, thereby identifying TCRs which have half lives slower than a first rate limit, and preferably faster than a second rate limit for use in adoptive T cell therapy. T cells transfected with TCRs not meeting those criteria are unlikely to produce significant T cell mediated immune response or are likely to produce non-specific T cell mediated immune responses.
- the present invention provides, in its broadest aspect, a method of treatment of a disease selected from cancer and infection comprising the administration to a subject suffering such disease a plurality of TCR-transfected T cells which are specifically activated by cells presenting a given pMHC characteristic of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC which is either:
- CD8 + T cell or (c) 0.9 seconds or slower in the case of a class ll-restricted TCR transfected into a CD4 + T cell.
- a second aspect of the invention provides the use of a plurality of TCR- transfected T cells which are specifically activated by cells presenting a given pMHC characteristic of cancer or infection, in the preparation of a composition for the treatment of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC which is either slower than that of the known corresponding wild type soluble TCR, or in the case where no corresponding wild-type TCR is known:
- the TCRs presented by each of said T cells has, in soluble form, a half-life for the interaction with the said pMHC which:
- (a) in the case of a class l-restricted TCR transfected into a CD8 + T cell is preferably 2 seconds or slower, for example 4 seconds or slower, or 9.6 seconds or slower, or (c) in the case of a class ll-restricted TCR transfected into a CD4 + T cell, is preferably 2 seconds or slower, for example 4 seconds or slower or 9.6 seconds or slower.
- TCR transfected T cells for use in the invention include, but are not limited to, those wherein, in addition to having the slower half life limitations mentioned above, at least some of the TCRs presented by said transfected T cells have, in soluble form, a half-life for the interaction with the said pMHC which is either
- At least some of the TCRs presented by said transfected T cells have, in soluble form, a half-life for the interaction with the said pMHC which:
- (b) in the case of a class l-restricted TCR transfected into a CD4 T cell, or in the case of class ll-restricted TCR transfected into a CD8 + T cell is preferably 300 minutes or faster, for example 162 minutes or faster, or 12 minutes or faster.
- Another aspect of the invention provides a method of treatment of a disease selected from cancer and infection comprising the administration to a subject suffering such disease a plurality of TCR-transfected CD4 + and/or CD8 + T cells which are specifically activated by cells presenting a given pMHC characteristic of such disease, at least some of the transfected TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC within the range from 9.6 seconds to 12 minutes.
- said TCRs have, in soluble form, a half-life for the interaction with the said pMHC within the range selected from on of the following:
- a further aspect of the invention provides the use of a plurality of TCR- transfected CD4 + and/or CD8 + T cells which are specifically activated by cells presenting a given pMHC characteristic of cancer or infection, in the preparation of a composition for the treatment of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half- life for the interaction with the said pMHC within the range from 9.6 seconds to
- said TCRs have, in soluble form, a half-life for the interaction with the said pMHC within the range selected from on of the following:
- the TCR transfected T cells used in the invention are either CD3 + CD4 +
- T cell response of said TCR transfected T cells to APCs expressing the peptide-MHC recognised by the transfected TCRs is “enhanced” compared to that of T cells transfected with the corresponding WT TCR. Said “enhanced” response may.
- T cells of the present invention take the form of an increased T cell response by T cells of the present invention to APCs presenting a fixed level of the cognate peptide- MHC compared to that seen with T cells transfected with the corresponding wild-type TCR and/or an lowering of the level of the cognate peptide-MHC present of the surface of APCs required in order to elicit a T cell response by the T cells of the invention compared to that seen with T cells transfected with the corresponding wild-type TCR.
- methods suitable for measuring this increased T cell response of the transfected T cells including cytokine release assays, killing assays or cell proliferation assays. Examples 5, 6 and 7 herein provide details of a cytokine release assay, a killing assay and a cell proliferation respectively suitable for measure the level of T cell response.
- One preferred embodiment of the present invention is provided by a method of taking a T cell-containing population of cells from a patient and transfecting said cells with a TCR having, in soluble form, a half-life for the interaction with the its cognate pMHC falling within the overlap range of preferred TCR half lives for transfection of CD4+ and CD8 + T cells. (9.6 seconds to 12 minutes)
- the transfected T cells obtained by this method will include both CD4 + and CD8 + T cells which are capable of being specifically activated by APCs presenting the cognate peptide-MHC for the transfected TCR.
- T cells can be divided into "Killer” and "Helper" sub-types.
- Killer T cells are capable of directly killing infected or cancerous cells and are generally characterised by the expression of a heterodimeric co-receptor (CD8 ⁇ ) giving these cells a CD3 + /CD8 + phenotype.
- Helper T cells are involved in initiating antibody-mediated responses to extracellular pathogens and these cells are characterised by the expression of a monomeric co-receptor (CD4) giving these cells a CD3 + /CD4 + phenotype.
- the TCR transfected T cells of the present invention are used to target abnormal cells presenting cancer or infection-specific pMHCs complexes.
- the pMHCs of cancerous cells may comprise peptides derived from proteins which are not expressed by corresponding non-cancerous cells and/or there may be abnormal levels of one or more normally occurring pMHC present of the surface of these cells.
- Pathogen including but not limited to viral and bacterial infection can also lead to characteristic changes in the pMHC profile of a subject. If the infectious agent actively enters the cells of the subject peptides derived from the agent are likely to be presented by Class I pMHCs on the surface of these cells.
- Class Il pMHCs comprising peptides from the infective agent may be presented by uninfected antigen presenting cells which have taken up the infectious agents from the blood or lymph fluid of a subject. The presentation of such infection-specific Class Il pMHC will facilitate an antibody-mediated immune response.
- mutated TCRs can be created by a number of methods, for example by the TCR phage method detailed in WO 2004/044004.
- TCRs can be produced by hybridising the amino acid sequences of WT and mutated TCRs, and/or by pairing the alpha and beta chains of a plurality of TCRs with the same pMHC specificity.
- the mutations required in order to produce TCRs from which can be selected those for use is the present invention may be made in any part of the TCR chains.
- these mutations may be made in sequences within the variable regions of said TCRs, such as the CDR3, CDR2, CDR1 or HV4 regions therein.
- TCRs for use in the present invention are defined by reference to their half lives (in soluble form) for their interactions with their cognate ligands. In order to measure the half-life of the interaction between a given soluble TCR and its cognate peptide-MHC soluble versions of the eventual transfectable TCR are produced. As will be known to those skilled in the art there are a number of TCR designs suitable for producing such soluble versions. Generally, these designs comprise TCR chains which have been truncated to remove the transmembrane regions thereof. WO 03/020763 describes the production and testing of soluble TCRs of a preferred design which utilises an introduced non- native disulfide interchain bond to facilitate the association of the truncated TCR chains. Details of other potentially suitable soluble TCR designs can be found in:
- WO 99/60120 which described the production of non-disulfide linked truncated TCR chains which utilise heterologous leucine zippers fused to the C-termini thereof to facilitate chain association
- WO 99/18129 which described the production of single-chain soluble TCRs comprising a TCR ⁇ variable domain covalently linked to a TCR ⁇ variable domain via a peptide linker.
- the measurement of the half-life of the interaction between a given soluble TCR and its cognate peptide-MHC ligand can be made by any of the known methods.
- a preferred method is the Surface Plasmon Resonance (Biacore) method of Example 2 herein.
- the data produced from the method described in Example 2 allows the following parameters for a given TCR / peptide-MHC interaction to be determined:
- K D Off-rate (k off ) / On-rate (k on )
- T 1/2 Ln2/Off-rate (k off )
- the T cells of the invention are transfected (either stably or transiently) with nucleic acids such that the latter are expressible in the cell. This will normal involve incorporating the nucleic acids into suitable expression vectors, of which many are known.
- the T cells can be infected ("transduced") with viruses or virus-derived proteins comprising nucleic acid or nucleic acids encoding TCRs.
- the T cells can be transfected with plasmids comprising nucleic acid or nucleic acids encoding TCRs, or the T cells can be incubated in the presence of "naked" nucleic acid or nucleic acids which encode TCRS s under conditions which allow the said nucleic acid or nucleic acid or nucleic acids to enter the T cells. Electroporation or lipofection are examples of methods typically used to enhance the entry of the "naked" or vector-borne TCR encoding nucleic acid or nucleic acids in to these T cells.
- the TCR-encoding nucleic acid or nucleic acids used in these transfection methods can be either DNA or RNA.
- nucleic acids of the invention are defined uniquely by their sequence information, they are intended to benefit from one or more of the following known general design considerations:
- tRNA transfer RNA
- Avoidance of other unwanted motifs For example, the removal of inappropriate messenger RNA splice sites or polyadenylation signals, and undesirable restriction enzyme recognition DNA sequences.
- translation initiation consensus signals (“Kozak” signals) 5' of the ORF, and/or a strong translation termination codon, such as TAA immediately 3 1 of the ORF, and/or efficient messenger RNA transcription termination signals.
- Optimisation of nucleic acid GC content - The overall ratio of CG: AT bases in a nucleic acid can also influence the rate of transcription and/or translation of a nucleic acid encoding a given polypeptide.
- the TCR-transfected T cells of the present invention can be used for the treatment of cancer including, but not limited to, the following cancers:
- the TCR-transfected T cells of the present invention can be used for the treatment of infection including, but not limited to, the following infectious diseases: HIV/AIDS, influenza and hepatitis.
- Figure 1a is the DNA sequence of the codon-optimised full-length wild-type 1 G4 NY-ESO TCR alpha chain.
- Figure 1b is the DNA sequence of the codon-optimised full-length wild-type 1G4 NY-ESO TCR beta chain.
- Figure 2a is the amino acid sequence of the full-length 1G4 NY-ESO TCR wild-type alpha chain.
- Figure 2b is the amino acid sequence of the full-length 1G4 NY-ESO TCR wild-type beta chain.
- Figure 3a is the DNA sequence of a soluble version of 1G4 NY-ESO TCR wild-type alpha chain including an introduced cysteine codon.
- the introduced cysteine codon is underlined.
- Figure 3b is the DNA sequence of is the DNA sequence of a soluble version of 1G4 NY-ESO TCR wild-type beta chain including an introduced cysteine codon. The introduced cysteine codon is underlined.
- Figure 4a is the amino acid sequence of a soluble version of 1G4 NY-ESO TCR wild-type alpha chain including an introduced cysteine codon. The introduced cysteine residue is highlighted.
- Figure 4b is the amino acid sequence of a soluble version of 1G4 NY-ESO TCR wild-type beta chain including an introduced cysteine codon. The introduced cysteine residue is highlighted.
- Figure 5a is the DNA sequence of the codon-optimised full-length wild-type HIV Gag TCR alpha chain.
- Figure 5b is the DNA sequence of the codon-optimised full-length wild-type HIV Gag TCR beta chain.
- Figure 6a is the amino acid sequence of the full-length wild-type HIV Gag TCR alpha chain.
- Figure 6b is the amino acid sequence of the full-length wild-type HIV TCR beta chain.
- Figure 7a is the DNA sequence of a soluble version of a wild-type HIV Gag TCR alpha chain including an introduced cysteine codon.
- the introduced cysteine codon is highlighted and the restriction enzyme recognition sites are underlined.
- Figure 7b is the DNA sequence of a soluble version of a wild-type HIV Gag TCR beta chain including an introduced cysteine codon.
- the introduced cysteine codon is highlighted and the restriction enzyme recognition sites are underlined.
- Figure 8a is the amino acid sequence of a soluble version of the wild-type HIV Gag TCR alpha chain including an introduced cysteine residue. The introduced cysteine residue is highlighted.
- Figure 8b is the amino acid sequence of a soluble version of the wild-type HIV Gag TCR beta chain including an introduced cysteine residue. The introduced cysteine residue is highlighted.
- Figure 9 is the DNA sequence of the pEX954 expression vector.
- Figure 10 is a plasmid map for the pEX954 expression vector.
- Figure 11 is the DNA sequence of the pEX821 expression vector.
- Figure 12 is the plasmid map for the pEX821 expression vector.
- Figure 13 is INF- ⁇ release ELISA data showing activation of T cells transfected with nucleic acid encoding 1G4 NY-ESO TCRs.
- Figure 14 is Chromium release data showing killing of APCs by CD8 + T cells transfected with nucleic acid encoding 1G4 NY-ESO TCRs.
- Figure 15 is Chromium release data showing killing of APCs by CD4 + T cells transfected with nucleic acid encoding 1G4 NY-ESO TCRs.
- Figure 16 is FACS data showing proliferation of CD8 + T cells transfected with nucleic acid encoding HIV Gag TCRs.
- Figure 17 is FACS data showing proliferation of CD4 + T cells transfected with nucleic acid encoding HIV Gag TCRs.
- Figure 18 is a diagram plotting the observed responses of T cells transfected with 1G4 NY-ESO TCRs against the Biacore-determined half-life of the corresponding soluble TCR.
- Example 1 Production of soluble disulfide linked versions of 1G4 NY-ESO and HIV Gag TCRs.
- Figures 3a and 3b provide the DNA sequences of the TCR alpha and beta chains of a soluble version of the wild-type 1G4 NY-ESO TCR. Each of these DNA sequences contains an introduced cysteine codon which is underlined.
- Figures 7a and 7b provide the DNA sequences of the TCR alpha and beta chains of a soluble version of the wild-type HIV Gag TCR. Each of these DNA sequences contains an introduced cysteine codon which is underlined.
- pGMT7-based expression plasmids which contain the T7 promoter for high level expression in E.coli strain BL21-DE3(pLysS (Pan et al.,
- CIaI and SaIII restriction enzyme recognition sites were introduced into the above TCR alpha chain DNA sequences and these were ligated into pEX954 cut with CIaI and Xhol. (See Figures 9 and 10 respectively for the DNA sequence and plasmid map of the pEX954 vector).
- Asel and Agel restriction enzyme recognition sites were introduced into the above TCR beta chain DNA sequences and these were ligated into pEX821 cut with Ndel/Agel. (See Figures 11 and 12 respectively for the DNA sequence and plasmid map of the pEX821 vector).
- the cut TCR alpha and beta chain DNA and cut vector were ligated using a rapid DNA ligation kit (Roche) following the manufacturers instructions.
- Ligated plasmids were transformed into competent E.coli strain XL1-blue cells and plated out on LB/agar plates containing 100mg/ml ampicillin. Following incubation overnight at 37 0 C 1 single colonies were picked and grown in 10 ml LB containing 100 ⁇ g/ml ampicillin overnight at 37 0 C with shaking. Cloned plasmids were purified using a Miniprep kit (Qiagen) and the insert was sequenced using an automated DNA sequencer (Lark Technologies).
- Figures 4a and 4b respectively are the soluble disulfide linked wild-type 1G4 TCR ⁇ and ⁇ chain amino acid sequences produced from the DNA sequences of Figures 3a and 3b
- Figures 8a and 8b respectively are the soluble disulfide linked wild-type HIV gag TCR ⁇ and ⁇ chain amino acid sequences produced from the DNA sequences of Figures 7a and 7b
- Suitable mutated TCRs can be identified by a number of methods, for example by the TCR phage display method detailed in WO 2004/044004.
- Soluble versions of these mutated TCRs are produced by altering the DNA sequence encoding the corresponding wild-type or wild-type TCR chain to produce the required mutations.
- Example 2 Biacore surface plasmon resonance characterisation of sTCR binding to specific pMHC.
- a surface plasmon resonance biosensor (Biacore 3000TM ) was used to analyse the binding of a sTCR to its peptide-MHC ligand. This was facilitated by producing single pMHC complexes (described below) which were immobilised to a streptavid in-coated binding surface in a semi-oriented fashion, allowing efficient testing of the binding of a soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously. Manual injection of HLA complex allows the precise level of immobilised class I MHC molecules to be manipulated easily.
- HLA-A * 0201 molecules were refolded in vitro from bacterially-expressed inclusion bodies containing the constituent subunit proteins and synthetic epitope peptide, followed by purification and in vitro enzymatic biotinylation (O'Callaghan et al. (1999) Anal. Biochem. 266: 9-15).
- HLA-A*0201-heavy chain was expressed with a C-terminal biotinylation tag which replaces the transmembrane and cytoplasmic domains of the protein in an appropriate construct.
- Inclusion body expression levels of ⁇ 75 mg/litre bacterial culture were obtained.
- the MHC light-chain ( ⁇ 2-microglobulin) was also expressed as inclusion bodies in E.coli from an appropriate construct, at a level of ⁇ 500 mg/litre bacterial culture.
- E. coli cells were lysed and inclusion bodies are purified to approximately 80% purity.
- Protein from inclusion bodies was denatured in 6 M guanidine-HCI, 50 mM Ths pH 8.1 , 100 mM NaCI, 10 mM DTT, 10 mM EDTA 1 and was refolded at a concentration of 30 mg/litre heavy chain, 30 mg/litre ⁇ 2microglobulin into 0.4 M L-Arginine-HCI, 100 mM Tris pH 8.1 , 3.7 mM cystamine, 6.6 mM cysteamine, 4 mg/ml of the cognate epitope peptide required to be loaded by the HLA-A*0201 molecule, by addition of a single pulse of denatured protein into refold buffer at ⁇ 5 0 C. Refolding was allowed to reach completion at 4 0 C for at least 1 hour.
- Buffer was exchanged by dialysis in 10 volumes of 10 mM Tris pH 8.1. Two changes of buffer were necessary to reduce the ionic strength of the solution sufficiently.
- the .protein solution was then filtered through a 1.5 ⁇ m cellulose acetate filter and loaded onto a POROS 50HQ anion exchange column (8 ml bed volume). Protein was eluted with a linear 0-500 mM NaCI gradient. HLA- A * 0201 -peptide complex eluted at approximately 250 mM NaCI, and peak fractions were collected, a cocktail of protease inhibitors (Calbiochem) was added and the fractions were chilled on ice.
- Biotinylation tagged pMHC molecules were buffer exchanged into 10 mM Tris pH 8.1 , 5 mM NaCI using a Pharmacia fast desalting column equilibrated in the same buffer. Immediately upon elution, the protein-containing fractions were chilled on ice and protease inhibitor cocktail (Calbiochem) was added. Biotinylation reagents were then added: 1 mM biotin, 5 mM ATP (buffered to pH 8), 7.5 mM MgCI2, and 5 ⁇ g/ml BirA enzyme (purified according to O'Callaghan et al. (1999) Anal. Biochem. 266: 9-15). The mixture was then allowed to incubate at room temperature overnight.
- the biotinylated pHLA-A*0201 molecules were purified using gel filtration chromatography. A Pharmacia Superdex 75 HR 10/30 column was pre- equilibrated with filtered PBS and 1 ml of the biotinylation reaction mixture was loaded and the column was developed with PBS at 0.5 ml/min. Biotinylated pHLA-A * 0201 molecules eluted as a single peak at approximately 15 ml. Fractions containing protein were pooled, chilled on ice, and protease inhibitor cocktail was added. Protein concentration was determined using a Coomassie-binding assay (PerBio) and aliquots of biotinylated pHLA-A*0201 molecules were stored frozen at -2O 0 C. Streptavidin was immobilised by standard amine coupling methods.
- PerBio Coomassie-binding assay
- Such immobilised complexes are capable of binding both T-cell receptors and the coreceptor CD8 ⁇ , both of which may be injected in the soluble phase. Specific binding of TCR is obtained even at low concentrations (at least 40 ⁇ g/ml), implying the TCR is relatively stable.
- the pMHC binding properties of soluble TCR (sTCR) are observed to be qualitatively and quantitatively similar if sTCR is used either in the soluble or immobilised phase. This is an important control for partial activity of soluble species and also suggests that biotinylated pMHC complexes are biologically as active as non-biotinylated complexes.
- SPR surface plasmon resonance
- K D was determined by experimentally measuring the dissociation rate constant, kd, and the association rate constant, ka.
- the equilibrium constant K D was calculated as kd/ka.
- TCR was injected over two different cells one coated with ⁇ 300 RU of the cognate peptide-HLA-A2*0201 complex, the second coated with -300 RU of non-specific peptide-HLA-A * 0201 complex.
- Flow rate was set at 50 ⁇ l/min. Typically 250 ⁇ l of TCR at ⁇ 3 ⁇ M concentration was injected. Buffer was then flowed over until the response had returned to baseline.
- Kinetic parameters were calculated using Biaevaluation software. The dissociation phase was also fitted to a single exponential decay equation enabling calculation of half- life.
- Example 3 Production of codon optimised DNA and RNA encoding full length 1G4 NY-ESO and HIV Gag TCRs.
- Figures 1 a and 1 b provide the DNA sequences of the TGR alpha and beta chains of codon-optimised full-length wild-type 1G4 NY-ESO TCR.
- Figures 5a and 5b provide the DNA sequences of the TCR alpha and beta chains of codon-optimised full-length wild-type HIV Gag TCR.
- Restriction enzyme recognition sites can be added to these DNA sequences in order to facilitate ligation of these DNA sequences into appropriate gene expression vectors.
- appropriate gene expression vectors include retroviral vectors such as derivatives of the MSCV-based splice-gag vector (pMSGV) which is described in Hughes et al., (2005) Hum Gene Then 16: 457-472. Retroviral packaging and T cell transduction can then be carried out according to Zhao et al. (2005) J Immunol. 174 : 4415-4423.
- TCRs genes can be evaluated by transfection of T cells using in-vitro transcribed (IVT) RNA corresponding to the TCR DNA sequences provided herein. See Zhao et al. (2006) MoI. Ther.
- PCR primers were designed to amplify plasmid- encoded TCR genes and introduce a T7 promoter at the 5 1 end and a polyA tract at the 3' the genes for the alpha and beta TCR chains respectively.
- RNA was generated via in vitro transcription.
- Figures 2a and 2b respectively are the full-length wild-type 1G4 TCR ⁇ and ⁇ chain amino acid sequences produced from the DNA sequences of Figures 1a and 1b
- Figures 6a and 6b respectively are the full-length wild-type HIV gag TCR ⁇ and ⁇ chain amino acid sequences produced from the DNA sequences of Figures 5a and 5b
- Mutated IG4 NY-ESO TCRs or HIV Gag TCRs can be identified by a number of methods, for example by the. TCR phage display method detailed in WO 2004/044004. The mutations thus identified can be introduced into the full length gene optimised DNA or RNA sequences encoding the wild-type or wild- type TCR chains.
- Example 4 Electroporation of T cells with IVT RNA encoding IG4 NY-ESO TCRs.
- Electroporation of anti-CD3 antibody (OKT3) stimulated human PBLs and cell lines with IVT RNA encoding the 1G4 NY-ESO TCRs was conducted as described in Zhao et al. (2006) MoI. Ther. 13: 151-159.
- the RNA encoding the WT NY-ESO TCR alpha chain sequence corresponds to the DNA sequence provided in Figure 1a.
- the RNA encoding the WT NY- ESO TCR beta chain sequence corresponds to the DNA sequence provided in Figure 1b.
- PBL Peripheral Blood Lymphocyte
- TCRs have Biacore-determined monomer half-lives of 2.2 seconds, 9.6 seconds, 19 seconds, 41 seconds, 74 seconds, 4 minutes, 12 minutes , 98 minutes and 425 minutes respectively.
- T2 APCs were pulsed with cognate or non-cognate peptides in R/10 medium for 2 hrs at 37°C, followed by washing (three times) before initiation of co- cultures.
- the TCR transfected T cells and responder APC cells were co- cultured for 24 h. Cytokine secretion was measured in culture supernatants diluted to be in the linear range of the assay.
- the illustrative IFN- ⁇ release data presented in Figure 13 shows that CD4 + T cells transfected with the wild-type (WT), c5/c100, c10/c1 and c12c2 mutant 1G4 NY-ESO TCRs respond to APCs in a cognate antigen specific manner.
- CD4 + T cells transfected with the wild-type (WT) 1G4 NY-ESO TCRs only respond significantly to the cognate peptide when the APCs are pulsed at high (non-physiologically-relevant) peptide levels.
- the data on IFN- ⁇ release from CD8 + T cells transfected with the wild-type (WT) and c12c2 mutant 1G4 NY-ESO TCRs demonstrates that these transfected T cells respond to APCs in a cognate antigen specific manner.
- the data on IFN- ⁇ gamma release from CD8+ T cells transfected with the c58/c61 , c5/c100, and c10c1 mutant 1G4 NY-ESO TCRs demonstrates that these transfected T cells respond to APCs in a non-cognate antigen specific manner.
- IFN- ⁇ release data (not shown) demonstrates that CD8 + T cells transfected with the wt/263, 269/wt, wt/266 and 259/263 mutated 1G4 NY-ESO TCRs respond to APCs in a cognate antigen specific manner.
- CD8 + T cells transduced to express the wild- type (WT) wt/263,259/wt, wt/266, 259/263 and c12c2 mutant 1G4 TCRs (which have Biacore determined monomer half-lives of 2.2 seconds, 9.6 seconds, 19 seconds, 41 seconds, 74 seconds and 4 minutes respectively) respond specifically to APCs presenting a physiologically relevant level of the cognate antigen.
- CD8 + T cells transfected with the c58/c61 , c5/c100 and c10/c1 mutant 1G4 NY-ESO TCRs (which have Biacore determined monomer half-lives of 425 minutes, 98 minutes, 12 minutes respectively) also respond to APCs presenting non-cognate antigen.
- CD4 + T cells transduced to express wt/263, 259/wt, wt/266, 259/263, c12/c2, c10/c1 , c5/c100, mutant 1G4 TCRs (which have Biacore determined monomer half-lives of 9.6 seconds, 19 seconds, 41 seconds, 74 seconds, 4 minutes, 12 minutes and 98 minutes respectively) respond to APCs in a "physiologically relevant" cognate antigen-specific manner.
- CD4 + T cells transfected with the c58/c61 mutant 1G4 NY-ESO TCRs which has a Biacore determined monomer half-life of 425 minutes
- T cells transfected with WT and mutant 1G4 NY-ESO TCRs were measured using a chromium ( 51 Cr) release assay. Briefly, 1x10 6 target APCs were labeled for 1 h at 37°C with 200 ⁇ Ci of 51 Cr sodium chromate (GE Healthcare, Piscataway, NJ). Labeled target cells (5x10 3 ) were incubated with effector cells at the ratios indicated in the text for 4 h at 37°C in 0.2 ml of R/10 medium. Harvested supernatants were counted using a Wallac 1470 Wizard gamma counter (PerkinElmer, Wellesley, MA).
- the killing data presented in Figure 14 shows that CD8 + T cells transfected with the wild-type (WT) and wt/c59 mutant 1G4 NY-ESO TCRs respond to peptide pulsed APCs in a cognate antigen specific manner.
- the killing data presented in Figure 15 shows that CD4 + T cells transfected with the wild-type (WT) and c10/c1 c5/c100 and wt/c59 mutant 1G4 NY-ESO TCRs respond to peptide pulsed APCs in a cognate antigen specific manner.
- Example 7 Dye depletion HIV Gag TCR transduced T cells proliferation assay.
- T cells were transduced with DNA encoding the wild-type and mutated HIV Gag TCRs using methods substantially as described in Parry et al., (2003) J. lmmunol ⁇ 7 ⁇ : 166-174. Briefly, TCR ⁇ chain and TCR ⁇ chain encoding DNA sequences were inserted together into a Lentiviral expression vector.
- This vector contains DNA encoding both the TCR ⁇ chain and ⁇ chain as a single open reading frame with the in-frame Foot and Mouth Disease Virus (FMDV) 2A cleavage factor amino acid sequence (LLNFDLLKLAGDVESNPG (SEQ ID NO: 1)) separating the TCR chains, (de Felipe et al., (2004) Genet Vaccines Ther 2 (1): 13) On mRNA translation the TCR ⁇ chain is produced with the 2A peptide sequence at its C-terminus and the TCR ⁇ chain is produced as a separate polypeptide.
- FMDV Foot and Mouth Disease Virus
- CD8 + and CD4 + T cells transduced with HIV Gag TCRs to proliferate in the presence of either untransfected K562 APCs or K562 APCs transfected to express the cognate Gag HIV epitope was assessed. This was carried by FACs analysis of the transduced T cells which had been stained with carboxyfluorescein diactetate succinimidyl ester (CFSE).
- CFSE is a dye which is can passively diffuse into cells and then reacts with intracellular amines to form fluorescent conjugates which are retained within the cell. Proliferation of the stained T cells can be monitored by a reduction in the average fluorescent of the T cells which occurs as the cells divide and the dye is then diluted between the parent and daughter cells.
- Figures 16 and 17 provide FACs data from HIV Gag TCR transduced CD8+ T cells and CD4+T cells respectively.
- Figure 16 shows that CD8 + T cells transduced to express the wild-type wild- type HIV Gag TCR (WT) and CD8 + T cells transduced to express the mutated c11/wt, wt/c6 and d 1/c6 HIV Gag TCR proliferate in the present of K562 APCs expressing the cognate HIV Gag epitope. T cells transduced to express the c11/c6 mutated HIV Gag TCR also proliferate in the presence of K562 . APCs which do not express the cognate epitope.
- Figure 17 shows that CD4 + T cells transduced to express the wild-type wild- type HIV Gag TCR (WT) and CD4 + T cells transduced to express the mutated c11/wt, wt/c6 and c11/c6 HIV Gag TCR proliferate only in the presence of K562 APCs expressing the cognate HIV Gag epitope.
- CD8 + T cells transduced to express the WT, c11/wt and wt/c6 mutant HIV Gag TCRs (which have Biacore determined monomer half-lives of 31 seconds, 7.7 minutes and 12 minutes respectively) respond to APCs in a cognate antigen-specific manner.
- CD8 + T cells transduced to express the c11/c6 mutant HIV Gag TCR (which has a Biacore determined monomer half-life of 162 minutes) responds weakly to APCs in a non-cognate antigen-specific manner.
- the upper limit of TCR half-life for cognate antigen-specific T cell responses in CD8 + T cells lies between 12 and 162 minutes.
- the Biacore-determined monomer affinity (K 0 ) of the c11/wt HIV Gag TCR is 8.7nM which is close to the determined affinity of the c5/c100 1G4 NY-ESO TCR which when transfected into CD8+ T cells leads to non-cognate antigen-specific T cell function.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
This invention provides a method of treating cancer or infection by administering T cells transfected with T cell receptors (TCRs) which in their soluble form have a half life for their interaction with their cognate peptide- MHC complex chosen to enhance the avidity of the T cells for target cells presenting that peptide MHC complex while maintaining the activation specificity of the T cells by that peptide-MHC complex.
Description
T cell Therapies
This invention relates to a method of treating cancer or infection by administering T cells transfected with T cell receptors (TCRs) which in their soluble form have a half life for their interaction with their cognate peptide- MHC complex chosen to enhance the avidity of the T cells for target cells presenting that peptide MHC complex while maintaining the activation specificity of the T cells by that peptide-MHC complex.
Background to the Invention
Immunotherapy involves enhancing the immune response of a patient to cancerous or infected cells. Active immunotherapy is carried out by stimulation of the endogenous immune system of tumour bearing patients. Passive, or adoptive, immunotherapy involves the transfer of immune competent cells into the patient. (Paul (2002) Curr Gene Therapy 2: 91-100) There are three broad approaches to adoptive immunotherapy which have been applied in the clinic for the treatment of metastatic diseases; lymphokine-activated killer (LAK) cells, auto-lymphocyte therapy (ALT) and tumour-infiltrating lymphocytes (TIL). (Paul (2002) Curr Gene Therapy 2: 91- 100).
One variation of T cell adoptive therapy is the use of gene therapy techniques to introduce TCRs specific for known cancer-specific MHC-peptide complexes into the T cells of cancer patients. For example, WO 01/55366 discloses retrovirus-based methods for transfecting, preferably, T cells with heterologous TCRs. This document states that these transfected cells could be used for either the cell surface display of TCR variants as a means of identifying high affinity TCRs or for immunotherapy. Methods for the molecular cloning of cDNA of a human p53-specific, HLA restricted murine TCR and the transfer of this cDNA to human T cells are described in published US patent application no. 20020064521. This document states that the expression of this murine TCR results in the recognition of endogenously processed human p53 expressed in tumour cells pulsed with the p53-derived peptide 149-157
presented by HLA A*0201 and claims the use of the murine TCR in anticancer adoptive immunotherapy. However, the concentration of peptide pulsing required achieving half maximal T cell stimulation of the transfected T cells was approximately 250 times that required by T cells expressing solely the murine TCR. As the authors noted "The difference in level of peptide sensitivity is what might be expected of a transfectant line that contained multiple different TCR heterodimers as a result of independent association of all four expressed hu and mu TCR chains."
There are also a number of papers relating to T cell adoptive therapy. In one study (Rosenberg (1988) N Engl J Med 319 (25): 1676-80) lymphocytes from melanomas were expanded in vitro and these tumor-infiltrating lymphocytes, in combination with IL-2 were used to treat 20 patients with metastatic melanoma by means of adoptive transfer. The authors note that objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. A further study describes the administration of an expanded population of Melan-A specific cytotoxic T cells to eight patients with refractory malignant melanoma. These T cells were administered by i.v. infusion at fortnightly intervals, accompanied by s.c. administration of IL-2. The T cell infusions were well tolerated with clinical responses noted as one partial, one mixed with shrinkage of one metastatic deposit and one no change (12 months) among the eight patients.
(Meidenbauer (2003) J Immunol 170: 2161-2169) As noted in this study, recent advances regarding the in vitro stimulation T cells for the generation of cell populations suitable for T cell adoptive therapy have made this approach more practical. See, for example (Oelke (2000) Clin Cancer Res 6: 1997- 2005) and (Szmania (2001 ) Blood 98: 505-12).
It has therefore been recognised in the art that it would be desirable to improve the immune response of T-cells administered in adoptive therapy. The expectation has been that T-cells transfected with TCRs having high
affinities for their cognate p-MHCs would produce the desired improvement in immune response.
It has recently become possible to create TCRs having high and specific in vitro affinities for their respective pMHCs. Phage display provides one means by which libraries of TCR variants can be generated. Methods suitable for the phage display and subsequent screening of libraries of TCR variants each containing a non-native disulfide interchain bond are detailed in (Li et a/., (2005) Nature Biotech 23 (3): 349-354) and WO 2004/04404.
Holler et.al. 2001 J. Exp. Med, 194, (8):1043-1052 states that various models have predicted that activation (of T-cells) is limited to a narrow window of TCR characteristics such as affinities, dissociation rates, half life of interaction and the like, for the TCR-pMHC interaction, and the affinity of the antigenic peptide for its cognate MHC, and that above or below this window the T-cells will fail to undergo activation. However, the paper comes to no definitive conclusion regarding which is the controlling parameter defining that "window" or the values that define said window. The paper reports that in some experiments using CD8- T-cell hybridomas transfected with a high affinity (KD = 10 nM) mutant TCR activation could be detected at lower peptide concentrations than with T-cell hybridomas expressing the wild type TCR. The paper states, based on those results: "... It also may indicate that the in-vitro engineering of TCRs for higher affinity could prove useful for increasing the activity of T cells against particular pMHC targets, for example in adoptive T cell therapies."
Holler et. al. (2003) Nat. Immunol. 4 (1): 55-62 showed that T-cells transfected with a high affinity TCR were non-specifically activated, and therefore potentially dangerously autoreactive. The paper concludes "It is possible that in vitro engineering of TCRs with precise affinities against self or foreign pMHC ligands could be performed to optimise this balance between favourable T cell activity and dangerous autoreactivity.
Despite the recognition in the art of the desirability of using high affinity TCRs for transfection of TCRs to increase T cell-mediated immune responses, and
the assumption in the art that there exists a balance between the level of affinity of a TCR and the loss of specificity of activation of the transfected T- cell by the TCR's cognate pMHC, no studies have been reported which seek to map the range of affinities of TCRs which avoid non-specific activation of the transfected T-cells. Furthermore, although Holler et.al. 2001 J. Exp. Med, 194, (8): 1043-1052 refers to theories which rely on other characteristics of the T cell activation process, the art does not establish which characteristic other than affinity may be determinative of increased pMHC-specific T cell mediated immune response.
One recent study (Morgan et. al: (2006) Science 314 (5796): 126-129) details the use of autologous lymphocytes transduced ex-vivo with genes encoding a wild-type MART-1 specific TCR to treat 15 patients with metastatic melanoma. Two of these patients demonstrated a sustained regression of their metastatic melanoma as assessed by standard RECIST criteria. This study also states "Engineering PBL to express high affinity TCR recognising the NY-ESO-1 or the p53 antigen, as shown in Figure 1 A and table S1 , enables the in-vitro recognition of tumour-associated antigens expressed on a variety of common cancers and the use of these genetically engineered cells for the treatment of patients with common epithelial cancers deserves evaluation". However, this study does not provide any data regarding their affinity or APC-recognition efficacy in comparison to PBL transfected with the corresponding wild-type TCRs and the high level of peptide pulsing used in this in-vitro experiment (1μM) would be expected to result in a level of peptide-MHC presentation of the surface of the APCs used which was well above that found in under physiological conditions
Brief Description of the Invention This invention is based on the results of experiments which seek to establish the characteristic of the T cell activation process determinative of increased pMHC-specific T cell mediated immune response. The data has shown that pMHC-specific T-cell mediated immune responses can be enhanced if the T- cells are transfected with TCRs which, in soluble form, have a half life for their interaction with their cognate peptide-MHC ligands in a particular range. This
has enabled us to place numerical limits on the effective range of those half lives, thereby identifying TCRs which have half lives slower than a first rate limit, and preferably faster than a second rate limit for use in adoptive T cell therapy. T cells transfected with TCRs not meeting those criteria are unlikely to produce significant T cell mediated immune response or are likely to produce non-specific T cell mediated immune responses.
Detailed Description of the Invention
The present invention provides, in its broadest aspect, a method of treatment of a disease selected from cancer and infection comprising the administration to a subject suffering such disease a plurality of TCR-transfected T cells which are specifically activated by cells presenting a given pMHC characteristic of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC which is either:
slower than that of the known corresponding wild type soluble TCR, or in the case where no corresponding wild-type TCR is known:
(a) 1 second or slower in the case of a class l-restricted TCR transfected into a CD8+T cell, or
(b) 9.6 seconds or slower in the case of a class l-restricted TCR transfected into a CD4+T cell, or in the case of class ll-restricted TCR transfected into a
CD8+T cell, or (c) 0.9 seconds or slower in the case of a class ll-restricted TCR transfected into a CD4+T cell.
A second aspect of the invention provides the use of a plurality of TCR- transfected T cells which are specifically activated by cells presenting a given pMHC characteristic of cancer or infection, in the preparation of a composition for the treatment of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC which is either
slower than that of the known corresponding wild type soluble TCR, or in the case where no corresponding wild-type TCR is known:
(a) 1 second or slower in the case of a class l-restricted TCR transfected into a CD8+T cell, or
(b) 9.6 seconds or slower in the case of a class l-restricted TCR transfected into a CD4+ T cell, or in the case of class ll-restricted TCR transfected into a CD8+T cell, or
(c) 0.9 seconds or slower in the case of a class ll-restricted TCR transfected into a CD4+T cell.
In subsidiary embodiments of the invention, in the case where no corresponding wild-type TCR is known, the TCRs presented by each of said T cells has, in soluble form, a half-life for the interaction with the said pMHC which:
(a) in the case of a class l-restricted TCR transfected into a CD8+T cell is preferably 2 seconds or slower, for example 4 seconds or slower, or 9.6 seconds or slower, or (c) in the case of a class ll-restricted TCR transfected into a CD4+ T cell, is preferably 2 seconds or slower, for example 4 seconds or slower or 9.6 seconds or slower.
Preferably, TCR transfected T cells for use in the invention include, but are not limited to, those wherein, in addition to having the slower half life limitations mentioned above, at least some of the TCRs presented by said transfected T cells have, in soluble form, a half-life for the interaction with the said pMHC which is either
(a) 12 minutes or faster in the case of a class l-restricted TCR transfected into a CD8+ T cell, or
(b) faster than 425 minutes in the case of a class l-restricted TCR transfected into a CD4+T cell, or in the case of class ll-restricted TCR transfected into a CD8+ T cell, or
(c) 12 minutes or faster in the case of a class ll-restricted TCR transfected into a CD4+T cell.
In further subsidiary aspects of the invention, in addition to having the slower half life limitations mentioned above, at least some of the TCRs presented by said transfected T cells have, in soluble form, a half-life for the interaction with the said pMHC which:
(b) in the case of a class l-restricted TCR transfected into a CD4 T cell, or in the case of class ll-restricted TCR transfected into a CD8+ T cell is preferably 300 minutes or faster, for example 162 minutes or faster, or 12 minutes or faster.
Another aspect of the invention provides a method of treatment of a disease selected from cancer and infection comprising the administration to a subject suffering such disease a plurality of TCR-transfected CD4+ and/or CD8+ T cells which are specifically activated by cells presenting a given pMHC characteristic of such disease, at least some of the transfected TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC within the range from 9.6 seconds to 12 minutes. Preferably, said TCRs have, in soluble form, a half-life for the interaction with the said pMHC within the range selected from on of the following:
from 9.6 seconds to 4 minutes, or from 9.6 seconds to 74 seconds, or from 9.6 seconds to 41 seconds, or from 9.6 seconds to 19 seconds, or from 19 seconds to 12 minutes from 19 seconds to 4minutes, or from 19 seconds to 74 seconds, or from 19 seconds to 41 seconds, or from 41 seconds to 12 minutes, or from 41 seconds to 4 minutes, or
from 41 seconds to 74 seconds, or from 74 seconds to 12 minutes, or from 74 seconds to 4 minutes, or from 4 minutes to 12 minutes.
A further aspect of the invention provides the use of a plurality of TCR- transfected CD4+ and/or CD8+ T cells which are specifically activated by cells presenting a given pMHC characteristic of cancer or infection, in the preparation of a composition for the treatment of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half- life for the interaction with the said pMHC within the range from 9.6 seconds to
12 minutes. Preferably, said TCRs have, in soluble form, a half-life for the interaction with the said pMHC within the range selected from on of the following:
from 9.6 seconds to 4 minutes, or from 9.6 seconds to 74 seconds, or from 9.6 seconds to 41 seconds, or from 9.6 seconds to 19 seconds, or from 19 seconds to 12 minutes from 19 seconds to 4minutes, or from 19 seconds to 74 seconds, or from 19 seconds to 41 seconds, or from 41 seconds to 12 minutes, or from 41 seconds to 4 minutes, or from 41 seconds to 74 seconds, or from 74 seconds to 12 minutes, or from 74 seconds to 4 minutes, or from 4 minutes to 12 minutes.
The TCR transfected T cells used in the invention are either CD3+CD4+
"helper" T cells or most commonly, CD3+CD8+ "killer" T cells.
Certain preferred embodiments of the present invention are provided wherein the T cell response of said TCR transfected T cells to APCs expressing the peptide-MHC recognised by the transfected TCRs is "enhanced" compared to that of T cells transfected with the corresponding WT TCR. Said "enhanced" response may. take the form of an increased T cell response by T cells of the present invention to APCs presenting a fixed level of the cognate peptide- MHC compared to that seen with T cells transfected with the corresponding wild-type TCR and/or an lowering of the level of the cognate peptide-MHC present of the surface of APCs required in order to elicit a T cell response by the T cells of the invention compared to that seen with T cells transfected with the corresponding wild-type TCR. There are a number of methods suitable for measuring this increased T cell response of the transfected T cells including cytokine release assays, killing assays or cell proliferation assays. Examples 5, 6 and 7 herein provide details of a cytokine release assay, a killing assay and a cell proliferation respectively suitable for measure the level of T cell response.
One preferred embodiment of the present invention is provided by a method of taking a T cell-containing population of cells from a patient and transfecting said cells with a TCR having, in soluble form, a half-life for the interaction with the its cognate pMHC falling within the overlap range of preferred TCR half lives for transfection of CD4+ and CD8+ T cells. (9.6 seconds to 12 minutes) The transfected T cells obtained by this method will include both CD4+ and CD8+ T cells which are capable of being specifically activated by APCs presenting the cognate peptide-MHC for the transfected TCR.
T cells can be divided into "Killer" and "Helper" sub-types. Killer T cells are capable of directly killing infected or cancerous cells and are generally characterised by the expression of a heterodimeric co-receptor (CD8αβ) giving these cells a CD3+/CD8+ phenotype. Helper T cells are involved in initiating antibody-mediated responses to extracellular pathogens and these cells are characterised by the expression of a monomeric co-receptor (CD4) giving these cells a CD3+/CD4+ phenotype.
The TCR transfected T cells of the present invention are used to target abnormal cells presenting cancer or infection-specific pMHCs complexes. The pMHCs of cancerous cells may comprise peptides derived from proteins which are not expressed by corresponding non-cancerous cells and/or there may be abnormal levels of one or more normally occurring pMHC present of the surface of these cells. Pathogen (including but not limited to viral and bacterial) infection can also lead to characteristic changes in the pMHC profile of a subject. If the infectious agent actively enters the cells of the subject peptides derived from the agent are likely to be presented by Class I pMHCs on the surface of these cells. Additionally or alternatively, Class Il pMHCs comprising peptides from the infective agent may be presented by uninfected antigen presenting cells which have taken up the infectious agents from the blood or lymph fluid of a subject. The presentation of such infection-specific Class Il pMHC will facilitate an antibody-mediated immune response.
There are a number of known methods which can be used to produce and select mutated TCRs for use in the present invention. For example, mutated TCRs can be created by a number of methods, for example by the TCR phage method detailed in WO 2004/044004. Alternatively, or additionally, TCRs can be produced by hybridising the amino acid sequences of WT and mutated TCRs, and/or by pairing the alpha and beta chains of a plurality of TCRs with the same pMHC specificity.
The mutations required in order to produce TCRs from which can be selected those for use is the present invention may be made in any part of the TCR chains. For example, these mutations may be made in sequences within the variable regions of said TCRs, such as the CDR3, CDR2, CDR1 or HV4 regions therein.
TCRs for use in the present invention are defined by reference to their half lives (in soluble form) for their interactions with their cognate ligands. In order to measure the half-life of the interaction between a given soluble TCR and its cognate peptide-MHC soluble versions of the eventual transfectable TCR are produced. As will be known to those skilled in the art there are a number of
TCR designs suitable for producing such soluble versions. Generally, these designs comprise TCR chains which have been truncated to remove the transmembrane regions thereof. WO 03/020763 describes the production and testing of soluble TCRs of a preferred design which utilises an introduced non- native disulfide interchain bond to facilitate the association of the truncated TCR chains. Details of other potentially suitable soluble TCR designs can be found in:
WO 99/60120 which described the production of non-disulfide linked truncated TCR chains which utilise heterologous leucine zippers fused to the C-termini thereof to facilitate chain association, and
WO 99/18129 which described the production of single-chain soluble TCRs comprising a TCRα variable domain covalently linked to a TCRβ variable domain via a peptide linker.
The measurement of the half-life of the interaction between a given soluble TCR and its cognate peptide-MHC ligand can be made by any of the known methods. A preferred method is the Surface Plasmon Resonance (Biacore) method of Example 2 herein. The data produced from the method described in Example 2 allows the following parameters for a given TCR / peptide-MHC interaction to be determined:
Affinity (K0) for the interaction.
KD = Off-rate (koff) / On-rate (kon)
Half-life (T1/2) for the interaction.
T1/2 = Ln2/Off-rate (koff)
The T cells of the invention are transfected (either stably or transiently) with nucleic acids such that the latter are expressible in the cell. This will normal involve incorporating the nucleic acids into suitable expression vectors, of
which many are known. For example, the T cells can be infected ("transduced") with viruses or virus-derived proteins comprising nucleic acid or nucleic acids encoding TCRs. Alternatively, the T cells can be transfected with plasmids comprising nucleic acid or nucleic acids encoding TCRs, or the T cells can be incubated in the presence of "naked" nucleic acid or nucleic acids which encode TCRS s under conditions which allow the said nucleic acid or nucleic acid or nucleic acids to enter the T cells. Electroporation or lipofection are examples of methods typically used to enhance the entry of the "naked" or vector-borne TCR encoding nucleic acid or nucleic acids in to these T cells. The TCR-encoding nucleic acid or nucleic acids used in these transfection methods can be either DNA or RNA. The technology of recombinant DNA expression is well understood and described in many laboratory manuals and textbooks. (See, for example, Sambrook and Russell (2001) Molecular Cloning, a Laboratory Manual. 3rd edition, ISBN 0-87969-576-5) Examples 3 and 4 herein, provide suitable methods for carrying out the transfection of T cells with nucleic acid or nucleic acids encoding TCRs.
Although the nucleic acids of the invention are defined uniquely by their sequence information, they are intended to benefit from one or more of the following known general design considerations:
Relative abundance of transfer RNA (tRNA) - It is known that the cells of different species possess varying amounts of the tRNA molecules which each recognise the different codons which can be used to encode a given amino acid residue. Therefore, in general, it is preferable to use the codon recognised by the most abundance of these tRNA molecules. However, it may be advisable to use the selection of different codons encoding a given amino acid residues if these residue are encoded with high frequency within a subsequence of the nucleic acids, in order to prevent localised depletion of the most abundant tRNA species which may otherwise occur.
Removal of inverted repeat motifs - Such sequences introduce strong secondary structures, such as internal self hybridising "hair-pins", into nucleic
acids which may result in a slowing down of the translation process and a reduction of the level of expression.
Avoidance of other unwanted motifs - For example, the removal of inappropriate messenger RNA splice sites or polyadenylation signals, and undesirable restriction enzyme recognition DNA sequences.
Introduction of desired motifs - For example, translation initiation consensus signals ("Kozak" signals) 5' of the ORF, and/or a strong translation termination codon, such as TAA immediately 31 of the ORF, and/or efficient messenger RNA transcription termination signals.
Optimisation of nucleic acid GC content - The overall ratio of CG: AT bases in a nucleic acid can also influence the rate of transcription and/or translation of a nucleic acid encoding a given polypeptide.
Note however, it is not necessarily preferable to induce the fastest possible rate of transcription and/or translation. Overly high rates of either of these processes may result in the production of inappropriately folded and therefore inactive polypeptides. There are a number of companies that perform such gene codon optimisation as a service. GENEART AG, Germany is one such company.
The TCR-transfected T cells of the present invention can be used for the treatment of cancer including, but not limited to, the following cancers:
NY-ESO-positive, Telomerase-positive, Melan-A-positive, renal, ovarian, bowel, head & neck, testicular, lung, stomach, cervical, bladder, prostate or melanoma.
The TCR-transfected T cells of the present invention can be used for the treatment of infection including, but not limited to, the following infectious diseases:
HIV/AIDS, influenza and hepatitis.
Preferred features of each aspect of the invention are as for each of the other aspects mutatis mutandis. The prior art documents mentioned herein are incorporated to the fullest extent permitted by law.
Examples
The invention is further described in the following examples, which do not limit the scope of the invention in any way.
Reference is made in the following to the accompanying drawings in which:
Figure 1a is the DNA sequence of the codon-optimised full-length wild-type 1 G4 NY-ESO TCR alpha chain.
Figure 1b is the DNA sequence of the codon-optimised full-length wild-type 1G4 NY-ESO TCR beta chain.
Figure 2a is the amino acid sequence of the full-length 1G4 NY-ESO TCR wild-type alpha chain.
Figure 2b is the amino acid sequence of the full-length 1G4 NY-ESO TCR wild-type beta chain.
Figure 3a is the DNA sequence of a soluble version of 1G4 NY-ESO TCR wild-type alpha chain including an introduced cysteine codon. The introduced cysteine codon is underlined.
Figure 3b is the DNA sequence of is the DNA sequence of a soluble version of 1G4 NY-ESO TCR wild-type beta chain including an introduced cysteine codon. The introduced cysteine codon is underlined.
Figure 4a is the amino acid sequence of a soluble version of 1G4 NY-ESO TCR wild-type alpha chain including an introduced cysteine codon. The introduced cysteine residue is highlighted.
Figure 4b is the amino acid sequence of a soluble version of 1G4 NY-ESO TCR wild-type beta chain including an introduced cysteine codon. The introduced cysteine residue is highlighted.
Figure 5a is the DNA sequence of the codon-optimised full-length wild-type HIV Gag TCR alpha chain.
Figure 5b is the DNA sequence of the codon-optimised full-length wild-type HIV Gag TCR beta chain.
Figure 6a is the amino acid sequence of the full-length wild-type HIV Gag TCR alpha chain.
Figure 6b is the amino acid sequence of the full-length wild-type HIV TCR beta chain.
Figure 7a is the DNA sequence of a soluble version of a wild-type HIV Gag TCR alpha chain including an introduced cysteine codon. The introduced cysteine codon is highlighted and the restriction enzyme recognition sites are underlined.
Figure 7b is the DNA sequence of a soluble version of a wild-type HIV Gag TCR beta chain including an introduced cysteine codon. The introduced cysteine codon is highlighted and the restriction enzyme recognition sites are underlined.
Figure 8a is the amino acid sequence of a soluble version of the wild-type HIV Gag TCR alpha chain including an introduced cysteine residue. The introduced cysteine residue is highlighted.
Figure 8b is the amino acid sequence of a soluble version of the wild-type HIV Gag TCR beta chain including an introduced cysteine residue. The introduced cysteine residue is highlighted.
Figure 9 is the DNA sequence of the pEX954 expression vector.
Figure 10 is a plasmid map for the pEX954 expression vector.
Figure 11 is the DNA sequence of the pEX821 expression vector.
Figure 12 is the plasmid map for the pEX821 expression vector.
Figure 13 is INF-γ release ELISA data showing activation of T cells transfected with nucleic acid encoding 1G4 NY-ESO TCRs.
Figure 14 is Chromium release data showing killing of APCs by CD8+ T cells transfected with nucleic acid encoding 1G4 NY-ESO TCRs.
Figure 15 is Chromium release data showing killing of APCs by CD4+ T cells transfected with nucleic acid encoding 1G4 NY-ESO TCRs.
Figure 16 is FACS data showing proliferation of CD8+ T cells transfected with nucleic acid encoding HIV Gag TCRs.
Figure 17 is FACS data showing proliferation of CD4+ T cells transfected with nucleic acid encoding HIV Gag TCRs.
Figure 18 is a diagram plotting the observed responses of T cells transfected with 1G4 NY-ESO TCRs against the Biacore-determined half-life of the corresponding soluble TCR.
Example 1 - Production of soluble disulfide linked versions of 1G4 NY-ESO and HIV Gag TCRs.
Figures 3a and 3b provide the DNA sequences of the TCR alpha and beta chains of a soluble version of the wild-type 1G4 NY-ESO TCR. Each of these DNA sequences contains an introduced cysteine codon which is underlined.
Figures 7a and 7b provide the DNA sequences of the TCR alpha and beta chains of a soluble version of the wild-type HIV Gag TCR. Each of these DNA sequences contains an introduced cysteine codon which is underlined.
These DNA sequences can be synthesis de-novo by a number of contract research companies, for example GENEART AG (Germany).
Restriction enzyme recognition sites can be added to these DNA sequences in order to facilitate ligation of these DNA sequences into expression plasmids. pGMT7-based expression plasmids, which contain the T7 promoter for high level expression in E.coli strain BL21-DE3(pLysS (Pan et al.,
Biotechniqυes (2000) 29 (6): 1234-8) ) are appropriate expression vectors.
CIaI and SaIII restriction enzyme recognition sites were introduced into the above TCR alpha chain DNA sequences and these were ligated into pEX954 cut with CIaI and Xhol. (See Figures 9 and 10 respectively for the DNA sequence and plasmid map of the pEX954 vector).
Asel and Agel restriction enzyme recognition sites were introduced into the above TCR beta chain DNA sequences and these were ligated into pEX821 cut with Ndel/Agel. (See Figures 11 and 12 respectively for the DNA sequence and plasmid map of the pEX821 vector).
Restriction enzyme recognition sites as introduced into DNA encoding the TCR chains
CIaI - ATCGAT
SaIII - GTCGAC
Asel - ATTAAT
Agel - ACCGGT
Ligation
The cut TCR alpha and beta chain DNA and cut vector were ligated using a rapid DNA ligation kit (Roche) following the manufacturers instructions.
Ligated plasmids were transformed into competent E.coli strain XL1-blue cells and plated out on LB/agar plates containing 100mg/ml ampicillin. Following incubation overnight at 370C1 single colonies were picked and grown in 10 ml LB containing 100μg/ml ampicillin overnight at 370C with shaking. Cloned plasmids were purified using a Miniprep kit (Qiagen) and the insert was sequenced using an automated DNA sequencer (Lark Technologies).
Figures 4a and 4b respectively are the soluble disulfide linked wild-type 1G4 TCR α and β chain amino acid sequences produced from the DNA sequences of Figures 3a and 3b
Figures 8a and 8b respectively are the soluble disulfide linked wild-type HIV gag TCR α and β chain amino acid sequences produced from the DNA sequences of Figures 7a and 7b
The above methods can be used to produce soluble disulfide linked versions of mutated IG4 NY-ESO TCRs or HIV Gag TCRs. Suitable mutated TCRs can be identified by a number of methods, for example by the TCR phage display method detailed in WO 2004/044004.
Soluble versions of these mutated TCRs are produced by altering the DNA sequence encoding the corresponding wild-type or wild-type TCR chain to produce the required mutations.
Example 2 - Biacore surface plasmon resonance characterisation of sTCR binding to specific pMHC.
A surface plasmon resonance biosensor (Biacore 3000™ ) was used to analyse the binding of a sTCR to its peptide-MHC ligand. This was facilitated by producing single pMHC complexes (described below) which were immobilised to a streptavid in-coated binding surface in a semi-oriented fashion, allowing efficient testing of the binding of a soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously. Manual injection of HLA complex allows the precise level of immobilised class I MHC molecules to be manipulated easily.
Biotinylated class I HLA-A*0201 molecules were refolded in vitro from bacterially-expressed inclusion bodies containing the constituent subunit proteins and synthetic epitope peptide, followed by purification and in vitro enzymatic biotinylation (O'Callaghan et al. (1999) Anal. Biochem. 266: 9-15). HLA-A*0201-heavy chain was expressed with a C-terminal biotinylation tag which replaces the transmembrane and cytoplasmic domains of the protein in an appropriate construct. Inclusion body expression levels of ~75 mg/litre bacterial culture were obtained. The MHC light-chain (β2-microglobulin) was also expressed as inclusion bodies in E.coli from an appropriate construct, at a level of ~500 mg/litre bacterial culture.
E. coli cells were lysed and inclusion bodies are purified to approximately 80% purity. Protein from inclusion bodies was denatured in 6 M guanidine-HCI, 50 mM Ths pH 8.1 , 100 mM NaCI, 10 mM DTT, 10 mM EDTA1 and was refolded at a concentration of 30 mg/litre heavy chain, 30 mg/litre β2microglobulin into 0.4 M L-Arginine-HCI, 100 mM Tris pH 8.1 , 3.7 mM cystamine, 6.6 mM cysteamine, 4 mg/ml of the cognate epitope peptide required to be loaded by the HLA-A*0201 molecule, by addition of a single pulse of denatured protein into refold buffer at < 50C. Refolding was allowed to reach completion at 40C for at least 1 hour.
Buffer was exchanged by dialysis in 10 volumes of 10 mM Tris pH 8.1. Two changes of buffer were necessary to reduce the ionic strength of the solution sufficiently. The .protein solution was then filtered through a 1.5μm cellulose
acetate filter and loaded onto a POROS 50HQ anion exchange column (8 ml bed volume). Protein was eluted with a linear 0-500 mM NaCI gradient. HLA- A*0201 -peptide complex eluted at approximately 250 mM NaCI, and peak fractions were collected, a cocktail of protease inhibitors (Calbiochem) was added and the fractions were chilled on ice.
Biotinylation tagged pMHC molecules were buffer exchanged into 10 mM Tris pH 8.1 , 5 mM NaCI using a Pharmacia fast desalting column equilibrated in the same buffer. Immediately upon elution, the protein-containing fractions were chilled on ice and protease inhibitor cocktail (Calbiochem) was added. Biotinylation reagents were then added: 1 mM biotin, 5 mM ATP (buffered to pH 8), 7.5 mM MgCI2, and 5 μg/ml BirA enzyme (purified according to O'Callaghan et al. (1999) Anal. Biochem. 266: 9-15). The mixture was then allowed to incubate at room temperature overnight.
The biotinylated pHLA-A*0201 molecules were purified using gel filtration chromatography. A Pharmacia Superdex 75 HR 10/30 column was pre- equilibrated with filtered PBS and 1 ml of the biotinylation reaction mixture was loaded and the column was developed with PBS at 0.5 ml/min. Biotinylated pHLA-A*0201 molecules eluted as a single peak at approximately 15 ml. Fractions containing protein were pooled, chilled on ice, and protease inhibitor cocktail was added. Protein concentration was determined using a Coomassie-binding assay (PerBio) and aliquots of biotinylated pHLA-A*0201 molecules were stored frozen at -2O0C. Streptavidin was immobilised by standard amine coupling methods.
Such immobilised complexes are capable of binding both T-cell receptors and the coreceptor CD8αα, both of which may be injected in the soluble phase. Specific binding of TCR is obtained even at low concentrations (at least 40μg/ml), implying the TCR is relatively stable. The pMHC binding properties of soluble TCR (sTCR) are observed to be qualitatively and quantitatively similar if sTCR is used either in the soluble or immobilised phase. This is an important control for partial activity of soluble species and also suggests that
biotinylated pMHC complexes are biologically as active as non-biotinylated complexes.
The interactions between sTCR containing a novel inter-chain bond and its ligand/ MHC complex or an irrelevant HLA-peptide combination, the production of which is described above, were analysed on a Biacore 3000™ surface plasmon resonance (SPR) biosensor. SPR measures changes in refractive index expressed in response units (RU) near a sensor surface within a small flow cell, a principle that can be used to detect receptor ligand interactions and to analyse their affinity and kinetic parameters. The probe flow cells were prepared by immobilising the pMHC complexes in flow cells via biotin-tag binding. The assay was then performed by passing sTCR over the surfaces of the different flow cells at a constant flow rate, measuring the SPR response in doing so.
To measure Equilibrium binding constant
Serial dilutions of WT sTCR were prepared and injected at constant flow rate of 5 μl min-1 over two different flow cells; one coated with ~1000 RU of the cognate peptide-HLA-A*0201 complex, the second coated with ~1000 RU of non-specific peptide-HLA-A*0201 complex. Response was normalised for each concentration using the measurement from the control cell. Normalised data response was plotted versus concentration of TCR sample and fitted to a hyperbola in order to calculate the equilibrium binding constant, KD. (Price & Dwek, Principles and Problems in Physical Chemistry for Biochemists (2nd Edition) 1979, Clarendon Press, Oxford).
To measure Kinetic Parameters
For high affinity TCRs KD was determined by experimentally measuring the dissociation rate constant, kd, and the association rate constant, ka. The equilibrium constant KD was calculated as kd/ka.
TCR was injected over two different cells one coated with ~300 RU of the cognate peptide-HLA-A2*0201 complex, the second coated with -300 RU of
non-specific peptide-HLA-A*0201 complex. Flow rate was set at 50 μl/min. Typically 250 μl of TCR at ~3 μM concentration was injected. Buffer was then flowed over until the response had returned to baseline. Kinetic parameters were calculated using Biaevaluation software. The dissociation phase was also fitted to a single exponential decay equation enabling calculation of half- life.
Results
The following tables summarise the Biacore determined affinity (K0) and half- lives for the interaction between soluble disulfide-linked versions of WT 1G4 NY-ESO and WT HIV GAG TCRs and several mutants thereof, identified, made and tested by the above procedures, and their cognate peptide-MHC complexes.
1G4 NY-ESO-based TCRs
HIV Gag-based TCRs
Example 3 - Production of codon optimised DNA and RNA encoding full length 1G4 NY-ESO and HIV Gag TCRs.
Figures 1 a and 1 b provide the DNA sequences of the TGR alpha and beta chains of codon-optimised full-length wild-type 1G4 NY-ESO TCR.
Figures 5a and 5b provide the DNA sequences of the TCR alpha and beta chains of codon-optimised full-length wild-type HIV Gag TCR.
These DNA sequences can be synthesis de-novo by a number of contract research companies, for example GENEART AG (Germany).
Restriction enzyme recognition sites can be added to these DNA sequences in order to facilitate ligation of these DNA sequences into appropriate gene expression vectors. Examples of such appropriate gene expression vectors include retroviral vectors such as derivatives of the MSCV-based splice-gag vector (pMSGV) which is described in Hughes et al., (2005) Hum Gene Then 16: 457-472. Retroviral packaging and T cell transduction can then be carried out according to Zhao et al. (2005) J Immunol. 174 : 4415-4423. Alternatively, TCRs genes can be evaluated by transfection of T cells using in-vitro transcribed (IVT) RNA corresponding to the TCR DNA sequences provided herein. See Zhao et al. (2006) MoI. Ther. 13: 151-159 for details of the methods required. Briefly, PCR primers were designed to amplify plasmid- encoded TCR genes and introduce a T7 promoter at the 51 end and a polyA tract at the 3' the genes for the alpha and beta TCR chains respectively. By using these purified PCR products as templates, RNA was generated via in vitro transcription.
Figures 2a and 2b respectively are the full-length wild-type 1G4 TCR α and β chain amino acid sequences produced from the DNA sequences of Figures 1a and 1b
Figures 6a and 6b respectively are the full-length wild-type HIV gag TCR α and β chain amino acid sequences produced from the DNA sequences of Figures 5a and 5b
Mutated IG4 NY-ESO TCRs or HIV Gag TCRs can be identified by a number of methods, for example by the. TCR phage display method detailed in WO 2004/044004. The mutations thus identified can be introduced into the full length gene optimised DNA or RNA sequences encoding the wild-type or wild- type TCR chains.
Example 4 - Electroporation of T cells with IVT RNA encoding IG4 NY-ESO TCRs.
Electroporation of anti-CD3 antibody (OKT3) stimulated human PBLs and cell lines with IVT RNA encoding the 1G4 NY-ESO TCRs was conducted as described in Zhao et al. (2006) MoI. Ther. 13: 151-159.
The RNA encoding the WT NY-ESO TCR alpha chain sequence corresponds to the DNA sequence provided in Figure 1a. The RNA encoding the WT NY- ESO TCR beta chain sequence corresponds to the DNA sequence provided in Figure 1b.
Results
The 1G4 TCR IVT RNA transfection efficiency levels obtained were between 30% and 75%. (FACS analysis using PE-labelled streptavidin cognate peptide-HLA-A*0201 tetramer staining was used to determine these values).
Example 5 Cytokine release ELISA assays of CD8+ and CD4+ T cells transfected with 1G4 NY-ESO TCRs
Peripheral Blood Lymphocyte (PBL) T cell cultures were transfected with IVT RNA encoding the following 1 G4 NY-ESO TCRs:
WT, wt/263,259/wt, wt/266, 259/263, c12/c2. c10/c1 , c5/c100 and c58/c61.
These TCRs have Biacore-determined monomer half-lives of 2.2 seconds, 9.6 seconds, 19 seconds, 41 seconds, 74 seconds, 4 minutes, 12 minutes , 98 minutes and 425 minutes respectively.
These transfected T cells were tested for reactivity in cytokine release assays using a commercially available ELISA kit (IFN-γ; Endogen, Cambridge, MA). T2 APCs were pulsed with cognate or non-cognate peptides in R/10 medium for 2 hrs at 37°C, followed by washing (three times) before initiation of co- cultures. The TCR transfected T cells and responder APC cells were co- cultured for 24 h. Cytokine secretion was measured in culture supernatants diluted to be in the linear range of the assay.
Results
The illustrative IFN-γ release data presented in Figure 13 shows that CD4+ T cells transfected with the wild-type (WT), c5/c100, c10/c1 and c12c2 mutant 1G4 NY-ESO TCRs respond to APCs in a cognate antigen specific manner. However, CD4+ T cells transfected with the wild-type (WT) 1G4 NY-ESO TCRs only respond significantly to the cognate peptide when the APCs are pulsed at high (non-physiologically-relevant) peptide levels. (1OnM or higher) Further IFN-γ release data (not shown) demonstrates that CD4+ T cells transfected with the wt/263, 269/wt, wt/266 and 259/263 mutated 1G4 NY- ESO TCRs respond to APCs in a cognate antigen specific manner.
The data presented in Figure 13 also shows that CD4+ T cells transfected with the c58/c61 mutant 1G4 NY-ESO TCRs respond to APCs in a non-cognate antigen specific manner.
The data on IFN-γ release from CD8+ T cells transfected with the wild-type (WT) and c12c2 mutant 1G4 NY-ESO TCRs demonstrates that these transfected T cells respond to APCs in a cognate antigen specific manner. The data on IFN-γ gamma release from CD8+ T cells transfected with the c58/c61 , c5/c100, and c10c1 mutant 1G4 NY-ESO TCRs demonstrates that these transfected T cells respond to APCs in a non-cognate antigen specific manner. Further IFN-γ release data (not shown) demonstrates that CD8+ T cells transfected with the wt/263, 269/wt, wt/266 and 259/263 mutated 1G4 NY-ESO TCRs respond to APCs in a cognate antigen specific manner.
Conclusions
These results demonstrate that CD8+ T cells transduced to express the wild- type (WT) wt/263,259/wt, wt/266, 259/263 and c12c2 mutant 1G4 TCRs (which have Biacore determined monomer half-lives of 2.2 seconds, 9.6 seconds, 19 seconds, 41 seconds, 74 seconds and 4 minutes respectively) respond specifically to APCs presenting a physiologically relevant level of the cognate antigen. CD8+ T cells transfected with the c58/c61 , c5/c100 and c10/c1 mutant 1G4 NY-ESO TCRs (which have Biacore determined monomer half-lives of 425 minutes, 98 minutes, 12 minutes respectively) also respond to APCs presenting non-cognate antigen.
These results demonstrate that the upper limit of TCR half-life for "physiologically-relevant" cognate antigen-specific T cells responses in CD8+ T cells lies between 4 and 12 minutes.
These results demonstrate that CD4+ T cells transduced to express wt/263, 259/wt, wt/266, 259/263, c12/c2, c10/c1 , c5/c100, mutant 1G4 TCRs (which have Biacore determined monomer half-lives of 9.6 seconds, 19 seconds, 41 seconds, 74 seconds, 4 minutes, 12 minutes and 98 minutes respectively)
respond to APCs in a "physiologically relevant" cognate antigen-specific manner. CD4+ T cells transfected with the c58/c61 mutant 1G4 NY-ESO TCRs (which has a Biacore determined monomer half-life of 425 minutes) also responded to APCs not presenting the cognate antigen.
These results demonstrate that the lower limit of TCR half-life for "physiologically-relevant" cognate antigen-specific T cells responses in CD4+ T cells lies between 2.2 and 9.6 seconds.
These results demonstrate that the upper limit of TCR half-life for cognate antigen-specific T cells responses in CD4+ T cells lies between 98 and 425 minutes.
Example 6 - Chromium release 1G4 NY-ESO TCR transfected T cell killing assay
The ability of T cells transfected with WT and mutant 1G4 NY-ESO TCRs to lyse antigen-specific peptide-pulsed target cells was measured using a chromium (51Cr) release assay. Briefly, 1x106 target APCs were labeled for 1 h at 37°C with 200 μCi of 51Cr sodium chromate (GE Healthcare, Piscataway, NJ). Labeled target cells (5x103) were incubated with effector cells at the ratios indicated in the text for 4 h at 37°C in 0.2 ml of R/10 medium. Harvested supernatants were counted using a Wallac 1470 Wizard gamma counter (PerkinElmer, Wellesley, MA). Total and spontaneous 51Cr release was determined by incubating 5x103 labeled target cells in either 2% SDS or R/10 medium for 4 h at 370C. Each data point was determined as an average of quadruplicate wells. The percent specific lysis was calculated as follows: % specific lysis = ((specific 51Cr release - spontaneous 51Cr release)/ (total 51Cr release - spontaneous 51Cr release)) x 100.
Results
The killing data presented in Figure 14 shows that CD8+ T cells transfected with the wild-type (WT) and wt/c59 mutant 1G4 NY-ESO TCRs respond to
peptide pulsed APCs in a cognate antigen specific manner. T cells transfected with the c10/c1 , c5/c100 and c58/c61 mutant 1G4 NY-ESO TCRs responded to peptide pulsed APCs in a non-cognate antigen specific manner.
The killing data presented in Figure 15 shows that CD4+ T cells transfected with the wild-type (WT) and c10/c1 c5/c100 and wt/c59 mutant 1G4 NY-ESO TCRs respond to peptide pulsed APCs in a cognate antigen specific manner. T cells transfected with the c58/c61 mutant 1G4 NY-ESO TCRs responded to peptide pulsed APCs in a non-cognate antigen specific manner.
Conclusions
These peptide-pulsed target APC lysis data broadly accord to that obtained by the IFN-y release ELISA assays detailed in Example 5 above.
Example 7 - Dye depletion HIV Gag TCR transduced T cells proliferation assay.
T cells were transduced with DNA encoding the wild-type and mutated HIV Gag TCRs using methods substantially as described in Parry et al., (2003) J. lmmunolΛ7Λ: 166-174. Briefly, TCR α chain and TCR β chain encoding DNA sequences were inserted together into a Lentiviral expression vector. This vector contains DNA encoding both the TCR α chain and β chain as a single open reading frame with the in-frame Foot and Mouth Disease Virus (FMDV) 2A cleavage factor amino acid sequence (LLNFDLLKLAGDVESNPG (SEQ ID NO: 1)) separating the TCR chains, (de Felipe et al., (2004) Genet Vaccines Ther 2 (1): 13) On mRNA translation the TCR α chain is produced with the 2A peptide sequence at its C-terminus and the TCR β chain is produced as a separate polypeptide.
The ability of CD8+ and CD4+ T cells transduced with HIV Gag TCRs to proliferate in the presence of either untransfected K562 APCs or K562 APCs transfected to express the cognate Gag HIV epitope was assessed. This was carried by FACs analysis of the transduced T cells which had been stained
with carboxyfluorescein diactetate succinimidyl ester (CFSE). CFSE is a dye which is can passively diffuse into cells and then reacts with intracellular amines to form fluorescent conjugates which are retained within the cell. Proliferation of the stained T cells can be monitored by a reduction in the average fluorescent of the T cells which occurs as the cells divide and the dye is then diluted between the parent and daughter cells. Figures 16 and 17 provide FACs data from HIV Gag TCR transduced CD8+ T cells and CD4+T cells respectively.
Results
Figure 16 shows that CD8+ T cells transduced to express the wild-type wild- type HIV Gag TCR (WT) and CD8+ T cells transduced to express the mutated c11/wt, wt/c6 and d 1/c6 HIV Gag TCR proliferate in the present of K562 APCs expressing the cognate HIV Gag epitope. T cells transduced to express the c11/c6 mutated HIV Gag TCR also proliferate in the presence of K562 . APCs which do not express the cognate epitope.
Figure 17 shows that CD4+ T cells transduced to express the wild-type wild- type HIV Gag TCR (WT) and CD4+T cells transduced to express the mutated c11/wt, wt/c6 and c11/c6 HIV Gag TCR proliferate only in the presence of K562 APCs expressing the cognate HIV Gag epitope.
Conclusion
These results demonstrate that CD8+ T cells transduced to express the WT, c11/wt and wt/c6 mutant HIV Gag TCRs (which have Biacore determined monomer half-lives of 31 seconds, 7.7 minutes and 12 minutes respectively) respond to APCs in a cognate antigen-specific manner. In contrast, CD8+ T cells transduced to express the c11/c6 mutant HIV Gag TCR (which has a Biacore determined monomer half-life of 162 minutes) responds weakly to APCs in a non-cognate antigen-specific manner.
These results demonstrate that the upper limit of TCR half-life for cognate antigen-specific T cell responses in CD8+ T cells lies between 12 and 162 minutes. This value is in broad agreement with the upper limit of TCR half-life for cognate antigen-specific T cell responses in CD8+ T cells of between 4 and 12 minutes determined by the IFN-γ release ELISA assay carried on T cells transfected with 1G4 NY-ESO TCRs. In combination, these two data-sets indicate that this half-life upper limit is approximately 12 minutes within the limits of the differing experimental methodologies.
These results demonstrate that the lower limit of TCR half-life for cognate antigen-specific T cell responses in CD4+ T cells is lower than 31 seconds. This value is in agreement with the lower limit of TCR half-life for cognate antigen-specific T cell responses in CD4+ T cells of between 2.2 and 9.6 seconds determined by the IFN-γ release ELISA assay carried on T cells transfected with 1 G4 NY-ESO TCRs.
These results also demonstrate that transduction of CD4+ T cells with mutated TCRs having half-lives longer than the corresponding WT TCR elicit an antigen-specific cell proliferation which is enhanced compared to that seen with CD4+ T cells transduced with the corresponding WT TCR. In contrast to the results obtained with transduced CD8+ T cells, CD4+ T cells transduced to express TCRs with half-lives of up to and including 162 minutes retain antigen specificity. Both these observations are in accordance with the IFN-γ release ELISA data obtained for CD4+ T cells transfected with 1G4 NY-ESO TCRs.
Finally, it should be noted that the Biacore-determined monomer half-life of a given TCR for its cognate pMHC has been established as the key interaction criterion predictive of cell function in T cells transfected with said TCRs. Figure 18 provides a diagrammatic summary of the effect of TCR half- life on the nature of T cell function observed for CD4+ and CD8+ T cells expressing said TCRs. To illustrate this further CD8+ T cells transfected with the c11/wt mutated HIV Gag TCR which has a Biacore-determined monomer half-life of 7.7 minutes would be expected to function in a cognate antigen specific manner and this is the case. However, the Biacore-determined
monomer affinity (K0) of the c11/wt HIV Gag TCR is 8.7nM which is close to the determined affinity of the c5/c100 1G4 NY-ESO TCR which when transfected into CD8+ T cells leads to non-cognate antigen-specific T cell function.
Claims
1. A method of treatment of a disease selected from cancer and infection comprising the administration to a subject suffering such disease a plurality of TCR-transfected T cells which are specifically activated by cells presenting a given pMHC characteristic of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC which is either
slower than that of the known corresponding wild type soluble TCR, or in the case where no corresponding wild-type TCR is known:
(a) 1 second or slower in the case of a class l-restricted TCR transfected into a CD8+T cell, or (b) 9.6 seconds or slower in the case of a class l-restricted TCR transfected into a CD4+ T cell, or in the case of class ll-restricted TCR transfected into a
CD8+ T cell, or
(c) 0.9 seconds or slower in the case of a class ll-restricted TCR transfected into a CD4+ T cell.
2. The use of a plurality of TCR-transfected T cells which are specifically activated by cells presenting a given pMHC characteristic of cancer or infection, in the preparation of a composition for the treatment of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC which is either
slower than that of the known corresponding wild type soluble TCR, or in the case where no corresponding wild-type TCR is known:
(a) 1 second or slower in the case of a class l-restricted TCR transfected into a CDe+T cell, or (b) 9.6 seconds or slower in the case of a class l-restricted TCR transfected into a CD4+ T cell, or in the case of class ll-restricted TCR transfected into a CD8+T cell, or
(c) 0.9 seconds or slower in the case of a class ll-restricted TCR transfected into a CD4+ T cell.
3. A method as claimed in claim 1 , or a use as claimed in claim 2, wherein at least some of the TCRs presented by said transfected T cells have, in soluble form, a half-life for the interaction with the said pMHC which is either
(a) 12 minutes or faster in the case of a class l-restricted TCR transfected into a CD8+ T cell, or
(b) faster than 425 minutes in the case of a class l-restricted TCR transfected into a CD4+T cell, or in the case of class ll-restricted TCR transfected into a CD8+ T cell, or
(c) 12 minutes or faster in the case of a class ll-restricted TCR transfected into a CD4+ T cell.
4. A method of treatment of a disease selected from cancer and infection comprising the administration to a subject suffering such disease a plurality of
TCR-transfected CD4+ and/or CD8+ T cells which are specifically activated by cells presenting a given pMHC characteristic of such disease, at least some of the transfected TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC within the range from 9.6 seconds to 12 minutes.
5. The use of a plurality of TCR-transfected CD4+ and/or CD8+ T cells which are specifically activated by cells presenting a given pMHC characteristic of cancer or infection, in the preparation of a composition for the treatment of such disease, at least some of the TCRs presented by each of said T cells having, in soluble form, a half-life for the interaction with the said pMHC within the range from 9.6 seconds to 12 minutes.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07823938A EP2087000A2 (en) | 2006-09-29 | 2007-09-26 | T cell therapies |
US12/443,078 US20100166722A1 (en) | 2006-09-29 | 2008-04-03 | T cell therapies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0619251A GB0619251D0 (en) | 2006-09-29 | 2006-09-29 | T cell therapies |
GB0619251.2 | 2006-09-29 | ||
GB0703406.9 | 2007-02-22 | ||
GB0703406A GB0703406D0 (en) | 2007-02-22 | 2007-02-22 | T Cell therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008038002A2 true WO2008038002A2 (en) | 2008-04-03 |
WO2008038002A3 WO2008038002A3 (en) | 2008-07-24 |
Family
ID=39230570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/003676 WO2008038002A2 (en) | 2006-09-29 | 2007-09-26 | T cell therapies |
Country Status (3)
Country | Link |
---|---|
US (1) | US20100166722A1 (en) |
EP (1) | EP2087000A2 (en) |
WO (1) | WO2008038002A2 (en) |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011001152A1 (en) | 2009-07-03 | 2011-01-06 | Immunocore Ltd | T cell receptors |
WO2012013913A1 (en) | 2010-07-28 | 2012-02-02 | Immunocore Ltd | T cell receptors |
WO2013041865A1 (en) | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
EP3211003A1 (en) * | 2016-02-24 | 2017-08-30 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
WO2017163064A1 (en) | 2016-03-23 | 2017-09-28 | Immunocore Limited | T cell receptors |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018148671A1 (en) | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US10344074B2 (en) | 2013-07-26 | 2019-07-09 | Adaptimmune Limited | T cell receptors |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
JP2021502815A (en) * | 2017-11-14 | 2021-02-04 | 中国科学院広州生物医薬与健康研究院Guangzhou Institutes Of Biomedicine And Health,Chinese Academy Of Sciences | Genetically modified γδ T cells |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
US11183272B2 (en) | 2018-12-21 | 2021-11-23 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
WO2022187280A1 (en) | 2021-03-01 | 2022-09-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
US12036240B2 (en) | 2019-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10526391B2 (en) | 2014-07-22 | 2020-01-07 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006129085A2 (en) * | 2005-06-01 | 2006-12-07 | Medigene Limited | High affinity melan-a t cell receptors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759243B2 (en) * | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
JP4111394B2 (en) * | 2003-12-22 | 2008-07-02 | 北海道ティー・エル・オー株式会社 | Method for producing modified targeted T cell and pharmaceutical |
CA2566363C (en) * | 2004-05-19 | 2014-12-16 | Avidex Ltd | High affinity ny-eso t cell receptor |
DK1791865T3 (en) * | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Cells expressing a modified T cell receptor |
-
2007
- 2007-09-26 WO PCT/GB2007/003676 patent/WO2008038002A2/en active Application Filing
- 2007-09-26 EP EP07823938A patent/EP2087000A2/en not_active Withdrawn
-
2008
- 2008-04-03 US US12/443,078 patent/US20100166722A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006129085A2 (en) * | 2005-06-01 | 2006-12-07 | Medigene Limited | High affinity melan-a t cell receptors |
Non-Patent Citations (5)
Title |
---|
CARRENO LEANDRO J ET AL: "The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge" IMMUNOLOGY, vol. 121, no. 2, June 2007 (2007-06), pages 227-237, XP002478786 ISSN: 0019-2805 * |
LI YI ET AL: "Directed evolution of human T-cell receptors with picomolar affinities by phage display" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 3, March 2005 (2005-03), pages 349-354, XP002336795 ISSN: 1087-0156 * |
MORGAN RICHARD A ET AL: "Cancer regression in patients after transfer of genetically engineered lymphocytes" SCIENCE (WASHINGTON D C), [Online] vol. 314, no. 5796, October 2006 (2006-10), pages 126-129, XP002478784 ISSN: 0036-8075 Retrieved from the Internet: URL:http://www.sciencemag.org/cgi/content/abstract/314/5796/126> [retrieved on 2008-04-28] * |
VAN DER MERWE P ANTON ET AL: "Molecular interactions mediating T cell antigen recognition." ANNUAL REVIEW OF IMMUNOLOGY 2003, vol. 21, 2003, pages 659-684, XP002478785 ISSN: 0732-0582 * |
ZHAO YANGBING ET AL: "High-affinity TCRs generated by phage display provide CD4(+) T cells with the ability to recognize and kill tumor cell lines" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 179, no. 9, November 2007 (2007-11), pages 5845-5854, XP002465972 ISSN: 0022-1767 * |
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
WO2011001152A1 (en) | 2009-07-03 | 2011-01-06 | Immunocore Ltd | T cell receptors |
WO2012013913A1 (en) | 2010-07-28 | 2012-02-02 | Immunocore Ltd | T cell receptors |
WO2013041865A1 (en) | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US10344074B2 (en) | 2013-07-26 | 2019-07-09 | Adaptimmune Limited | T cell receptors |
US11084862B2 (en) | 2013-07-26 | 2021-08-10 | Adaptimmune Limited | T cell receptors |
EP3578188A1 (en) | 2013-07-26 | 2019-12-11 | Adaptimmune Limited | T cell receptors |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11834718B2 (en) | 2013-11-25 | 2023-12-05 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
US11939637B2 (en) | 2014-12-19 | 2024-03-26 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
US11186825B2 (en) | 2015-10-28 | 2021-11-30 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 |
US11180730B2 (en) | 2015-10-28 | 2021-11-23 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
US11884717B2 (en) | 2015-11-19 | 2024-01-30 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
EP3211003A1 (en) * | 2016-02-24 | 2017-08-30 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
WO2017144621A1 (en) * | 2016-02-24 | 2017-08-31 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
WO2017163064A1 (en) | 2016-03-23 | 2017-09-28 | Immunocore Limited | T cell receptors |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11650211B2 (en) | 2017-02-12 | 2023-05-16 | Biontech Us Inc. | HLA-based methods and compositions and uses thereof |
EP4287191A2 (en) | 2017-02-12 | 2023-12-06 | BioNTech US Inc. | Hla-based methods and compositions and uses thereof |
WO2018148671A1 (en) | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US10864259B2 (en) | 2017-08-03 | 2020-12-15 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
EP4026554A1 (en) | 2017-08-03 | 2022-07-13 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
JP2021502815A (en) * | 2017-11-14 | 2021-02-04 | 中国科学院広州生物医薬与健康研究院Guangzhou Institutes Of Biomedicine And Health,Chinese Academy Of Sciences | Genetically modified γδ T cells |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11183272B2 (en) | 2018-12-21 | 2021-11-23 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
US12036240B2 (en) | 2019-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
WO2022187280A1 (en) | 2021-03-01 | 2022-09-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
Also Published As
Publication number | Publication date |
---|---|
WO2008038002A3 (en) | 2008-07-24 |
EP2087000A2 (en) | 2009-08-12 |
US20100166722A1 (en) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100166722A1 (en) | T cell therapies | |
US10800840B2 (en) | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer | |
Yee et al. | Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers | |
US8951510B2 (en) | T-cell receptor and nucleic acid encoding the receptor | |
Tan et al. | T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells | |
Schuler-Thurner et al. | Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells | |
Jorritsma et al. | Selecting highly affine and well-expressed TCRs for gene therapy of melanoma | |
Frankel et al. | Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase | |
WO2021068938A1 (en) | T cell receptor recognising kras mutation and encoding sequence thereof | |
JP2020127406A (en) | T cell receptors | |
JP2016525537A (en) | T cell receptor | |
US10654907B2 (en) | Methods and compositions for producing a cell expressing a T cell receptor | |
CA2410510A1 (en) | Artificial antigen presenting cells and methods of use thereof | |
Goff et al. | Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion | |
TW202146431A (en) | Chimeric receptors for use in engineered cells | |
AU2018239437A1 (en) | Antigen discovery for T cell receptors isolated from patient tumors recognizing wild-type antigens and potent peptide mimotopes | |
TW202144399A (en) | T cell receptor for identifying HPV antigen and coding sequence thereof | |
Zhang et al. | A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3. DP4‐peptide‐pulsed dendritic cells | |
KR20240018454A (en) | Methods for stimulating and transducing T cells | |
Grace et al. | Identification of highly cross-reactive mimotopes for a public T cell response in murine melanoma | |
WO2022098750A1 (en) | Hla class ii-restricted tcrs against the kras g12>v activating mutation | |
TW202140539A (en) | T cell receptor recognizing AFP antigen short peptide and encoding sequence thereof | |
TW202144401A (en) | T cell receptor recognizing AFP | |
WO2021139699A1 (en) | T cell receptor for recognizing afp and coding sequence thereof | |
AU2022377647A1 (en) | T cell receptor recognizing s37f mutation in ctnnb1 and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07823938 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007823938 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12443078 Country of ref document: US |